Build, Buy, Partner, or Walk Away in Healthtech: An NPV/IRR Scenario Model for the Decision

Direct answer: For a healthtech capability decision — say, a remote patient monitoring module, an EHR integration layer, or a new AI triage feature — run all four options (build, buy, partner, walk away) through the same NPV/IRR scenario model before you argue about them. Build usually looks cheapest on paper and is rarely cheapest after regulatory, security, and clinical-validation costs. Buy or partner often wins on time-to-revenue but carries integration and dependency risk. "Walk away" is a legitimate scenario that should carry a real NPV — the value of capital and attention redeployed elsewhere. The decision belongs to whichever option produces the best risk-adjusted NPV and a defensible IRR across a base, upside, and downside case.

Disclosure: I work on content for Percision, an AI strategic-intelligence platform. I'll explain where a tool like ours helps and where a spreadsheet or a human advisor is the better call.

Why healthtech breaks naive build-vs-buy math

Most build/buy analyses in software compare engineering cost against a license fee. Healthtech has cost layers that don't appear in a generic template, and ignoring them is how teams pick "build" and regret it 18 months later.

Costs that belong in every healthtech scenario:

• Regulatory and compliance: HIPAA controls, potential FDA pathway (SaMD / 510(k) / De Novo) for anything clinical, SOC 2, and ongoing audit cost.
• Clinical validation: evidence generation, clinician review, and the real possibility that a feature doesn't clear validation and must be reworked.
• Interoperability: FHIR/HL7 work, EHR integration (Epic, Cerner), and the maintenance tax as those standards evolve.
• Security and breach exposure: PHI raises the expected cost of a failure, which belongs in your downside case.
• Reimbursement dependency: if revenue relies on CPT codes or payer contracts, that timing and uncertainty drives the model more than build cost does.

A "buy" or "partner" option often absorbs some of these — a validated vendor may already hold clearances and integrations — which is exactly why comparing only headline prices is misleading.

The NPV/IRR scenario walkthrough

Run every option through the identical structure so the comparison is apples-to-apples.

Step 1 — Define the four options concretely. Not "build vs buy" in the abstract. "Build the monitoring engine in-house over 3 quarters," "license Vendor X's SDK," "co-develop with a partner under revenue share," "defer and revisit next fiscal year." Vague options produce vague models.

Step 2 — Lay out cash flows over a realistic horizon (5–7 years). For each option, project:

• Upfront and recurring costs (include the healthtech-specific layers above)
• Incremental revenue or retention value, with honest timing
• Terminal value or exit assumptions

Step 3 — Choose a discount rate you can defend. Use your actual cost of capital or a hurdle rate the board recognizes. Don't reverse-engineer a rate to make the answer you want.

Step 4 — Compute NPV and IRR per option. NPV tells you value created in today's dollars; IRR tells you the return rate, useful when you're comparing against other uses of the same capital. For "walk away," the NPV is what that capital earns in its next-best use — often not zero.

Step 5 — Build three scenarios per option. Base, upside, downside. In healthtech the swing variables usually are: regulatory clearance timeline, clinical-validation success, integration effort, and reimbursement/adoption ramp. Flex those, not just "revenue ±10%."

Step 6 — Stress the downside. What does "build" look like if FDA review adds nine months? What does "partner" look like if the partner is acquired or deprioritizes your roadmap? The option with the least catastrophic downside frequently wins even if its base case is second-best.

What "good" looks like: a positive risk-adjusted NPV, an IRR above your hurdle in the base case that stays acceptable in the downside, a clear-eyed view of which variable the whole decision hinges on, and a named owner for the top two risks.

Turning the model into a decision — and where Percision fits

A model that lives in one analyst's spreadsheet doesn't change a decision; a model the board trusts does. The gap between those two is structure, sensitivity analysis, and a clean narrative.

Percision is built to close that gap. You give it your business context, and it runs the situation through structured reasoning steps across specialist models — including NPV/IRR scenario modeling and DCF — to produce board-ready output: the scenario comparison, the financial model (Excel-exportable with an audit trail), a presentation deck, and the risks and assumptions stated plainly. It's positioned as a co-pilot, not autopilot — your leadership team supplies the clinical, regulatory, and market judgment the model can't invent, and stays in control of the call. The value is speed and depth: institutional-grade analysis in minutes instead of an 8–12 week engagement.

When you don't need a platform. If your decision is small, reversible, and the numbers are obvious, a one-page spreadsheet is enough — don't over-engineer it. If your challenge is deeply domain-specific — a novel FDA pathway strategy, a payer-contract negotiation, a clinical-evidence design — bring in a specialist consultant or regulatory advisor. A model can rank your options; it can't tell you whether your De Novo submission will clear. The best process often pairs both: rapid scenario modeling to frame the choice, expert human judgment to pressure-test the assumptions that matter most.

Independent research (for example, work published through Harvard Business School and BCG on generative AI and knowledge work) suggests AI tools can meaningfully speed up structured analytical tasks and lift quality on well-scoped problems — while also cautioning that AI can be confidently wrong outside its competence. That's the honest frame here: use the tool for structure and speed, keep humans on judgment.

FAQ

Should "walk away" always have a non-zero NPV? Usually, yes. Walking away frees capital, engineering capacity, and executive attention. Model the value of the next-best use of those resources rather than defaulting the option to zero — otherwise you'll systematically overbuild.

Which variable drives most healthtech build/buy models? Rarely the build cost itself. More often it's timeline-to-clearance, clinical-validation success, and reimbursement/adoption ramp. Run sensitivity on those first.

Can Percision replace our finance team or advisor on this? No. It compresses the analysis and produces board-ready models fast, but it's a co-pilot — your team and, for regulatory or clinical calls, a specialist should own the judgment and the final decision.

If you want to model build/buy/partner/walk-away across base, upside, and downside cases and get a board-ready deck out of it, you can run your scenario through Percision.